tbuckley/cabot-search huggingface dataset:
La psychothérapie peut-elle se passer de l’activation?
Authors: Mario Berta, J.C. Benoit
Journal: Psychotherapy and Psychosomatics (1974)

Research Articles| February 12 2010 La psychothérapie peut-elle se passer de l'activation? Subject Area: Psychiatry and Psychology Mario Berta; Mario Berta Centre Psychothérapique, Paris Search for other works by this author on: This Site PubMed Google Scholar J.C. Benoit J.C. Benoit Centre Psychothérapique, Paris Search for other works by this author on: This Site PubMed Google Scholar Psychother Psychosom (1974) 24 (4-6): 405–409. https://doi.org/10.1159/000286774 Article history Published Online: February 12 2010 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Mario Berta, J.C. Benoit; La psychothérapie peut-elle se passer de l'activation?. Psychother Psychosom 31 December 1974; 24 (4-6): 405–409. https://doi.org/10.1159/000286774 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsPsychotherapy and Psychosomatics Search Advanced Search Article PDF first page preview Close Modal This content is only available via PDF. 1974Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. You do not currently have access to this content.
THE TOTAL NON-PROTEIN NITROGEN OF THE BLOOD IN NEPHRITIS AND ALLIED CONDITIONS
Authors: Clifford B. Farr, J. Harold Austin
Journal: The Journal of Experimental Medicine (1913)

1. In a series of non-nephritic individuals the total non-protein nitrogen of the blood, determined by Folin's method, was found to lie between 15 and 43 milligrams per 100 cubic centimeters. From 50 to 60 per cent. of this was in the ammonia-urea fraction. 2. In cardiovascular disease with renal congestion, but without other renal lesion, there was no evidence of increase of non-protein nitrogen in the blood, nor of alteration of the ammonia-urea percentage. 3. In chronic nephritis with marked albuminuria and edema there was very little, if any, increase or alteration. 4. In chronic nephritis with hypertension the non-protein nitrogen was definitely increased, ranging from 40 to 180 milligrams per 100 cubic centimeters of blood. The percentage of the ammonia-urea fraction was usually higher than in non-nephritic cases. 5. Cases showing high non-protein nitrogen values were subject to rapid fluctuations in these values in the course of a few days. As a rule, clinical improvement was associated with a fall of the non-protein nitrogen figures to nearer the normal range. 6. Uremia was almost always accompanied by an increase of non-protein nitrogen in the blood, but no constant relation could be established between the degree of increase and the tendency to uremia. 7. Our cases have not yet been followed for a long enough period to admit of conclusions as to the possible relation between the degree of non-protein nitrogen retention and ultimate prognosis. 8. We believe this method to be a valuable aid in the clinical study of nephritis and that it can be readily carried out in any well equipped clinical laboratory.
Abstract 1506: Changes in the expression profile of microRNAs and their predicted targets in fibroblasts associated with breast carcinoma compared to fibroblasts from normal breast tissue.
Authors: Simone V. Costa, Rosimeire A. Roela, Fatima S. Pasini, Maria L H Katayama, Tatiane K. F. Mazzotti, Luiz H. Gebrim, Vanessa C.L. Resende, Miguel S. Neto, M Mitzi Brentani
Journal: Cancer Research (2013)

Abstract Background: Cancer-associated fibroblasts (CAFs) contribute to tumor growth and progression in breast cancer. CAFs are functional and phenotypically distinct from normal breast tissue (NAFs). Epigenetic modifications and post-transcriptional gene regulation by microRNAs may contribute to the phenotype of CAFs. Objective: To identify the changes in microRNAs expression profile in fibroblasts associated with breast cancer as compared to those observed in fibroblasts obtained from samples of mammoplasty. Methodology: Fibroblast primary culture from breast carcinoma (n= 04) and normal breast (n= 06) tissues were established and characterized by Immunohistochemistry. Total RNA extraction and purification were realized using Mirvana kit and miRNAs differentially expressed were identified by qPCR TaqMan® Low Density Array. Potential targets of these miRNAs were identified by in sílico analysis using DIANAm T, Miranda, miRWalk, PICTAR5 and TargetScan databases and compared to microarray profile determined using the U133 plus v.2 Affymetrix chip. Results: All primary cultures from fibroblast were characterized by presence of vimentin, total absence of CD31 and pan-cytokeratin expression but CAFs exhibited a higher proportion of cells positive for alpha-actin and S100A4. The five microRNAs differentially expressed identified by statistical analysis and grouped hierarchically (hs_miR_655, hs_miR_383, hs_miR_129_3p, hs_miR_15b, hs_miR_489) (FDR≤10% and p&amp;lt;0.05) allowed the separation of the samples into two distinct groups: NAFs and CAFs. The Gene Ontology analysis of predicted target genes to each one of the microRNAs listed above and also identified by microarray, revealed their involvement in important biological processes including cellular morphogenesis and protein localization. Further detailed studies of these miRNAs and their targets in CAFs may help to better understand the contribution of the mammary tumor microenvironment to breast carcinogenesis and progression. Financial Support: FAPESP 09/100088-7, FAPESP 2011/08194-3 Citation Format: Simone V. Costa, Rosimeire A. Roela, Fatima S. Pasini, Maria L H Katayama, Tatiane K. F. Mazzotti, Luiz H. Gebrim, Vanessa C.L. Resende, Miguel S. Neto, M Mitzi Brentani. Changes in the expression profile of microRNAs and their predicted targets in fibroblasts associated with breast carcinoma compared to fibroblasts from normal breast tissue. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1506. doi:10.1158/1538-7445.AM2013-1506
Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside
Authors: Alessandro Furlan, Zoulika Kherrouche, Rémi Montagne, Marie-Christine Copin, David Tulasne
Journal: Cancer Research (2014)

Met receptor tyrosine kinase was discovered in 1984 as an oncogene. Thirty years later, Met and its ligand hepatocyte growth factor/scatter factor are promising targets for the novel therapies developed to fight against cancers, with more than 240 clinical trials currently conducted. In this review, we offer to trace and highlight the most recent findings of the exemplary track record of research on Met receptor, which allowed moving this biomarker from bench to bedside. Indeed, three decades of basic research unravelled the structural basis of the ligand/receptor interaction and their complex downstream signaling network. During this period, animal models highlighted their crucial role in the development and homeostasis of epithelial organs. In parallel, involvement of Met in tumorigenesis was confirmed by the direct association of its deregulation to poor prognosis in numerous cancers. On the basis of these data, pharmaceutical companies developed many Met inhibitors, some of which are in phase III clinical trials. These impressive achievements should not detract from many questions that still remain, such as the precise Met signaling involvement in development or homeostasis of specific epithelial structures. In addition, the processes involving Met in resistance to current therapies or the appearance of resistances to Met-targeted therapies are far from being fully understood.
In Vitro and In Vivo Effects of Cisplatin on the Generation of Lymphokine-Activated Killer Cells
Authors: P. Allavena, P. Pirovano, C. Bonazzi, N. Colombo, A. Mantovani, M. D'Incalci
Journal: JNCI Journal of the National Cancer Institute (1990)

Pretreatment of human peripheral blood lymphocytes (PBL) with cisplatin (CDDP) before in vitro culture with interleukin-2 (IL-2) inhibited the generation of lymphokine-activated killer (LAK) cells and strongly inhibited proliferation. This inhibition was dose dependent, was significant only at concentrations greater than 6 μ M , and it required exposure to the drug for more than 1 hour. This period of IL-2 unresponsiveness was maximum at, 6 hours, but was spontaneously recovered within 24–48 hours and was more rapidly restored by increasing dosages of IL-2. Because inhibition of the generation of LAK cells by CDDP was observed only at relatively high levels ofexposure to the drug (<6μ M for <1 hr), it was important that we explore the in vivo significance of these findings. The peripheral blood lymphocytes from patients bearing ovarian adenocarcinoma collected 1 hour after an iv infusion of 50 mg of CDDP/m 2 were not inhibited, compared with those collected immediately before therapy. Relatively high levels of exposure to CDDP are required for inhibition of the generation of new cytotoxic effectors, most likely because of its antiproliferative effect. These results may bear relevance to approaches involving the combined use of CDDP and IL-2-LAK. [J Natl Cancer Inst 82: 139–142, 1990]
Necrosis Following Intravenous Use of Neo-Synephrine
Authors: E. Converse Peirce, Virgil B. Polley
Journal: New England Journal of Medicine (1954)

INTRAVENOUS administration of arterenol (levophed or nor-epinephrine) has been reported to cause tissue necrosis. This has occurred both with and without extravasation.1 2 3 4 The purpose of this paper is to report 2 cases that followed the intravenous use of Neo-Synephrine Hydrochloride as a pressor drug postoperatively. A search of the literature has revealed no similar cases.Case ReportsCase 1. A. H., a 52-year-old Negro, was admitted to the hospital for treatment of malignant hypertension. On November 21, 1952, a left thoracolumbar sympathectomy was performed by a transthoracic route. To combat hypotension on the day of operation Neo-Synephrine, 20 mg. per . . .
Efficacy of Oophorectomy in Lymphangioleiomyomatosis and Benign Metastasizing Leiomyoma
Authors: Arthur S. Banner, Charles B. Carrington, W. Brooks Emory, Frederick Kittle, George Leonard, Julius Ringus, Prentiss Taylor, Whitney W. Addington
Journal: New England Journal of Medicine (1981)

PROLIFERATION of smooth muscle within the lung can occur as a nonspecific finding in a variety of chronic lung diseases; it can also be the major histologic manifestation in two clinical entities: benign metastasizing leiomyoma (BML) and lymphangioleiomyomatosis (LAM). BML occurs predominantly in women and is thought to represent metastasis from a smooth-muscle tumor, usually a benign-appearing leiomyoma of the uterus. LAM occurs exclusively in women, usually during the child-bearing years, and is characterized by proliferation of smooth muscle along the lymphatic vessels of the abdomen, thorax, and lung, resulting in interstitial and obstructive lung disease, recurrent pneumothoraxes, and chylous . . .
385 MOLECULAR STAGES OF PDGFB DRIVEN LIVER FIBROSIS: LESONS FROM A TRANSGENIC MOUSE MODEL
Authors: J.U. Marquardt, T. Maass, M. Krupp, F. Staib, T. Gasier, J.B. Andersen, P.R. Galle, S.S. Thorgeirsson, A. Teufel
Journal: Journal of Hepatology (2012)
Graft and diblock copolymer multifunctional micelles for cancer chemotherapy and imaging
Authors: Hsieh-Chih Tsai, Wei-Hsiang Chang, Chun-Liang Lo, Cheng-Hung Tsai, Che-Hau Chang, Ta-Wei Ou, Tzu-Chen Yen, Ging-Ho Hsiue
Journal: Biomaterials (2009)
Goal directed meaning connects perception and specification
Authors: Patrick Foo, J. A. S. Kelso
Journal: Behavioral and Brain Sciences (2001)

We believe that the task goal in voluntary movements provides meaning to existing information sources in the environment and determines, in a dynamic way, the use and relative importance of these different sources. This task-centered meaning bridges the apparent controversy between what information is available in principle (i.e., specification), and what information is perceived.
Study into medical errors planned for the UK
Authors: J. Smith
Journal: BMJ (1999)

Investigators are seeking £1.2m to fund research into injuries caused by medical mismanagement in UK hospitals. Similar studies in New York, Colorado and Utah, and Australia have shown rates of adverse events caused by medical mismanagement of 3.7-10.6% of all admissions. A pilot study in London showed a rate of 6.7%.

The British study will use methods similar to those used in the US and Australian studies and the same definition of an adverse event—an injury caused by medical mismanagement that …
Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia
Authors: M Kontro, H Kuusanmäki, S Eldfors, T Burmeister, E I Andersson, Ø Bruserud, T H Brümmendorf, H Edgren, B T Gjertsen, M Itälä-Remes, S Lagström, O Lohi, T Lundán, J M L Martí, M M Majumder, A Parsons, T Pemovska, H Rajala, K Vettenranta, O Kallioniemi, S Mustjoki, K Porkka, C A Heckman
Journal: Leukemia (2014)
Low-Dose Aspirin Therapy for Chronic Stable Angina
Authors: Paul M. Ridker, JoAnn E. Manson, J. Michael Gaziano, Julie E. Buring, Charles H. Hennekens
Journal: Annals of Internal Medicine (1991)

Objective: To evaluate the efficacy of low-dose aspirin in the primary prevention of myocardial infarction among patients with chronic stable angina. Design: A randomized, double-blind, trial. Patients: The study included 333 men with baseline chronic stable angina but with no previous history of myocardial infarction, stroke, or transient ischemic attack who were enrolled in the Physicians' Health Study, a trial of aspirin among 22 071 male physicians. Intervention: Patients were randomly assigned to receive alternate-dayaspirin therapy (325 mg) or placebo and were followed for an average of 60. 2 months for the occurrence of myocardial infarction, stroke, or cardiovascular death. Results: During follow-up, 27 patients had confirmed myocardial infarctions; 7 were among the 178 patients with chronic stable angina who received aspirin therapy and 20 were among the 155 patients who received placebo (relative risk, 0. 30; 95% CI, 0.14 to 0.63; P = 0.003). While simultaneously controlling for other cardiovascular risk factors in a proportional hazards model, an overall 87% risk reduction was calculated (relative risk, 0.13; CI, 0.04 to 0.42; P < 0.001). For the subgroup of patients with chronic stable angina but no previous coronary bypass surgery or coronary angioplasty, an almost identical reduction in the risk for myocardial infarction was found (relative risk, 0.14; CI, 0.04 to 0.56; P = 0.006). Of 13 strokes, 11 occurred in the aspirin group and 2 in the placebo group (relative risk, 5.4; CI, 1.3 to 22.1; P = 0.02). No stroke was fatal, but 4 produced some long-term impairment of function. One stroke, in the aspirin group, was hemorrhagic. Conclusion: Our data indicated that alternate-day aspirin therapy greatly reduced the risk for first myocardial infarction among patients with chronic stable angina, a group of patients at high risk for cardiovascular death (P < 0. 001). Although our results for stroke were based on small numbers, they suggested an apparent increase in frequency of stroke with aspirin therapy; this finding requires confirmation in randomized trials of adequate sample size.
General Practice Research Database provides detailed anonymised data
Authors: M J Lockwood
Journal: BMJ (1996)

EDITOR,—Congratulations are due to Nicky Pearson and colleagues on their creation of a database of local morbidity data by aggregating the computerised medical records of general practitioners in Somerset.1 I wish to point out, however, that a large database already exists—namely, the General Practice Research Database, which is owned by the Department of Health; the Office of National Statistics (formerly the Office …
A Combinatorial Semaphorin Code Instructs the Initial Steps of Sensory Circuit Assembly in the Drosophila CNS
Authors: Zhuhao Wu, Lora B. Sweeney, Joseph C. Ayoob, Kayam Chak, Benjamin J. Andreone, Tomoko Ohyama, Rex Kerr, Liqun Luo, Marta Zlatic, Alex L. Kolodkin
Journal: Neuron (2011)
A single-LTR HIV-1 vector optimized for functional genomics applications
Authors: Hong Ma, Tal Kafri
Journal: Molecular Therapy (2004)

The development of high-throughput methods of converting simple expression cassettes into lentiviral vectors and expediting the process of retrieving vector genomes that carry candidate genes from host DNA will facilitate the use of lentiviral vectors as an efficient means of screening novel gene function. To optimize lentiviral vectors for functional genomic applications we have developed a shuttle HIV-1 vector containing a single LTR. Incorporation of a LoxP site and the Sbfl restriction enzyme site into the vector LTR allowed for the rescue of integrated vector genomes into individual bacterial clones. Vector DNA isolated from bacteria was used for a second round of functional screening. Furthermore, we identified a continuous DNA sequence containing all the cis elements required for vector production. Incorporating the isolated sequence into expression cassettes resulted in the generation of HIV-1 vectors in a single cloning step, which imparts a simplified procedure for converting cDNA expression cassettes into single-LTR lentiviral vectors.
Magnetic Resonance Imaging of the Lumbar Spine -- Terrific Test or Tar Baby?
Authors: Richard A. Deyo
Journal: New England Journal of Medicine (1994)

Back pain affects nearly half of all adults during a given year, and about two thirds of adults have back pain at some time in their lives. It is the second leading reason for visits to physicians in the United States and the leading cause of work-related disability1. Unfortunately, the cause of back problems is often obscure, in part because symptoms, anatomical findings, and imaging results may be only loosely associated. Thus, up to 85 percent of patients with low back pain cannot be given a definitive diagnosis2. This diagnostic uncertainty contributes to the large number of fads . . .
Basic fibroblast growth factor as a growth inhibitor for cultured human tumor cells.
Authors: L Schweigerer, G Neufeld, D Gospodarowicz
Journal: Journal of Clinical Investigation (1987)

Basic fibroblast growth factor (bFGF) stimulates the proliferation of many cells and it is found in a wide variety of normal or transformed tissues. As demonstrated here, bFGF is also present in cultured human Ewing's sarcoma cells. Unexpectedly, however, bFGF isolated from these cells inhibits their own proliferation, indicating that bFGF can act as an endogenous (autocrine) growth inhibitor for cultured Ewing's sarcoma cells. Since bFGF also inhibits the proliferation of some further tumor cells, but stimulates that of others, it can be considered a bifunctional regulator of tumor cell proliferation. The autocrine growth-inhibitory effect of bFGF in Ewing's sarcoma cells may explain the low mitotic activity of Ewing's sarcomas.
The Antigenicity of Hydroxyethyl Starch in Humans
Authors: Robert D. Brickman
Journal: JAMA (1966)

Hydroxyethyl is a waxy or branched starch which has been hydroxyethylated to retard intravascular hydrolysis. It is presently under consideration for use as a plasma expander. Previous studies with this starch have dealt mainly with its pharmacologic and physiologic properties in the normal and hypovolemic animal. Its therapeutic efficacy in hemorrhagic shock appears to be equal to or greater than clinical dextran, the present most commonly used plasma substitute.<sup>1</sup>(Clinical dextran is the term used here to refer to dextrans used by various investigators, and which are the subjects of the reports included in the listed references. There is a considerable range in molecular weight of these products; for specific information relative to each dextran mentioned, see the pertinent reference.) Dextran (average molecular weight from 40,000 to 80,000), is strongly antigenic for both man and animals.<sup>2,3</sup>Hydroxyethyl starch is also a high-molecular-weight polysaccharide, and if it is to
An IgG subclass imbalance in connective tissue disease.
Authors: R A Kay, K J Wood, R M Bernstein, P J Holt, R S Pumphrey
Journal: Annals of the Rheumatic Diseases (1988)

A group of 16 patients with a disproportionate polyclonal increase in their serum IgG1, resulting in raised concentrations of total IgG immunoglobulin, has been discovered. The other IgG subclasses in these patients are either normal or slightly reduced, resulting in an IgG1:IgG2 ratio of at least 10:1. Most cases are marked by the presence of anti-extractable nuclear antigen (anti-ENA) antibodies and high titres of rheumatoid factor and antinuclear antibody. All but one patient has a connective tissue disease, nearly twice the prevalence found in similarly hypergammaglobulinaemic patients without this IgG subclass imbalance. Among patients with systemic lupus erythematosus (SLE), those with the IgG1 disorder have a higher prevalence of high titre rheumatoid factor and antinuclear antibody, but a lower prevalence of anti-double-stranded DNA (anti-dsDNA) antibodies above 30 U/ml. It is suggested that this immunoglobulin abnormality may reflect a unique immunoregulatory dysfunction in these patients.
431 ICI 204,219: A potent, selective peptide leukotriene receptor antagonist
Authors: R.D. Krell, C.K. Buckner, R.A. Keith, D.W. Snyder, F.J. Brown, P.R. Bernstein, V. Matassa, Y.K. Yee, B. Hesp, R.E. Giles
Journal: Journal of Allergy and Clinical Immunology (1988)